Pulmonx director receives 40,000-share RSU award

Melenikiotou Georgia reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Melenikiotou Georgia reported acquisition or exercise transactions in this Form 4 filing.

Pulmonx Corp director Georgia Melenikiotou reported an equity compensation grant. She was awarded 40,000 shares of common stock as a grant of Restricted Stock Units on June 5, 2026, with no cash paid per share. Following this award, her direct holdings total 139,714 common shares.

The RSUs vest on the earlier of the one-year anniversary of the June 5, 2026 grant date, adjusted to the next business day if needed, or the date of the Annual Meeting of the Stockholders for the year after the grant.

Insider Trade Summary

Grant/Award: 40,000 shares

Grant/Award 1 txn

Insider Melenikiotou Georgia

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	40,000	$0.00	$0.00

Holdings After Transaction: Common Stock — 139,714 shares (Direct)

Footnotes (1)

1. F1. Represents grant of Restricted Stock Units ("RSU Grant") payable solely in common stock of the Issuer that vest on the earlier of (i) the one-year anniversary of the date of grant of June 5, 2026, or if such date is not a business day, then on the next business day, or (ii) the date of the Annual Meeting of the Stockholders for the year subsequent to the date such RSU Grant is made.

Key Figures

RSU grant size: 40,000 shares Grant price per share: $0.0000 per share Shares held after grant: 139,714 shares +1 more

4 metrics

RSU grant size 40,000 shares Restricted Stock Units granted June 5, 2026

Grant price per share $0.0000 per share Equity award, no cash paid

Shares held after grant 139,714 shares Total direct Pulmonx common shares following transaction

Vesting anniversary reference date June 5, 2026 One-year anniversary used in RSU vesting terms

Key Terms

Restricted Stock Units, Annual Meeting of the Stockholders, Common Stock

3 terms

Restricted Stock Units financial

"Represents grant of Restricted Stock Units ("RSU Grant") payable solely in common stock of the Issuer"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Annual Meeting of the Stockholders financial

"or (ii) the date of the Annual Meeting of the Stockholders for the year subsequent"

Common Stock financial

"payable solely in common stock of the Issuer"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Pulmonx (LUNG) report for Georgia Melenikiotou?

Pulmonx reported that director Georgia Melenikiotou received a grant of 40,000 Restricted Stock Units payable in common stock. This equity award is compensation, not an open-market purchase, and increases her direct ownership to 139,714 Pulmonx common shares following the transaction.

How many Pulmonx (LUNG) shares does Georgia Melenikiotou hold after this Form 4?

After the reported grant, Georgia Melenikiotou directly holds 139,714 Pulmonx common shares. This total includes the 40,000-share Restricted Stock Unit award disclosed in the filing, which was reported as a grant or award acquisition rather than a market transaction.

What are the vesting conditions for Georgia Melenikiotou’s Pulmonx (LUNG) RSU grant?

The 40,000 Restricted Stock Units vest on the earlier of the one-year anniversary of the June 5, 2026 grant date, adjusted to the next business day if needed, or the date of the Annual Meeting of Stockholders for the year after the grant is made.

Was Georgia Melenikiotou’s Pulmonx (LUNG) equity grant an open-market purchase?

No. The Form 4 identifies the transaction as a grant, award, or other acquisition of 40,000 Restricted Stock Units with a zero dollar price per share. It reflects equity compensation rather than an open-market buy or sell of Pulmonx stock.

What transaction code was used in Georgia Melenikiotou’s Pulmonx (LUNG) Form 4?

The filing uses transaction code “A,” which the document describes as a grant, award, or other acquisition. This code confirms the 40,000-share position change arises from an equity award, not from a discretionary market trade in Pulmonx shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/09/2026 - 05:56 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Melenikiotou Georgia

(Last) (First) (Middle)

C/O PULMONX CORPORATION

700 CHESAPEAKE DRIVE

(Street)

REDWOOD CITY CALIFORNIA 94063

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Pulmonx Corp [ LUNG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/05/2026		A		40,000(1)	A	$0	139,714	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents grant of Restricted Stock Units ("RSU Grant") payable solely in common stock of the Issuer that vest on the earlier of (i) the one-year anniversary of the date of grant of June 5, 2026, or if such date is not a business day, then on the next business day, or (ii) the date of the Annual Meeting of the Stockholders for the year subsequent to the date such RSU Grant is made.

	/s/ David Aaron Lehman, Attorney-in-Fact	06/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)